Survodutide (BI 456906): Dual GLP-1/Glucagon Receptor Agonist — Clinical Evidence in Obesity and MASH
Phase 2 clinical data on dual incretin/glucagon receptor co-agonism for metabolic disease.
Survodutide is a dual GLP-1 and glucagon receptor agonist in clinical development by Boehringer Ingelheim for obesity and metabolic dysfunction-associated steatohepatitis (MASH). This review summarizes the clinical evidence.
Overview
Survodutide (BI 456906) is an investigational dual agonist of the GLP-1 and glucagon receptors, developed by Boehringer Ingelheim in collaboration with Zealand Pharma. It is designed to combine the appetite-suppressing and insulinotropic effects of GLP-1 receptor activation with the glucagon-driven promotion of hepatic fat oxidation and energy expenditure, aiming for superior weight loss and liver benefit in metabolic disease.
Clinical Evidence
Obesity (Phase 2)
The phase 2 trial in obesity demonstrated dose-dependent weight loss, with the highest doses achieving mean body weight reductions in the range of 7–10% over 16 weeks, exceeding placebo and comparator GLP-1 agonist effects at comparable timepoints. Survodutide advanced to Phase 3 development for obesity based on these results.
MASH / NASH (Phase 2)
A Phase 2 trial in metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) reported a statistically significant proportion of patients achieving MASH resolution without worsening of fibrosis, a key registrational endpoint. These results supported advancement to Phase 3 in MASH.
Mechanistic Rationale
The dual-agonist design leverages complementary physiology: GLP-1 receptor activation reduces appetite and postprandial glucose excursion, while glucagon receptor activation stimulates hepatic fat oxidation and gluconeogenesis (the latter counterbalanced by GLP-1). The net metabolic effect is weight loss combined with reduction in hepatic steatosis — a profile particularly relevant to MASH.
Safety Considerations
Adverse events are primarily gastrointestinal (nausea, vomiting, diarrhea), consistent with the GLP-1 agonist class. Phase 3 programs are collecting long-term cardiovascular and liver-related safety data.
Evidence Assessment
Survodutide is supported by active Phase 2 clinical trials with positive efficacy in both obesity and MASH, and has advanced to Phase 3 development. It represents a high-evidence-tier intervention within the metabolic and weight management category.
Keywords
Research Goals
(2)Referenced Compounds
(8)The Growth Hormone Stack
Synergistic GHRH + GHRP combination for optimized pituitary GH pulse stimulation.
Tesofensine
Triple monoamine reuptake inhibitor examined for CNS approach to appetite signaling.
AOD-9604
Modified C-terminal GH fragment studied for selective fat metabolism activity.
CagriSema
Cagrilintide + semaglutide combination. REDEFINE 1: 22.7% mean body weight loss at 68 weeks.
Survodutide
Dual GLP-1/glucagon receptor agonist. Phase 3 SYNCHRONIZE-1: 16.6% weight loss.
Semaglutide
A long-acting GLP-1 receptor agonist with one of the most extensive research bodies of any modern peptide.
Retatrutide
A triple-receptor agonist (GLP-1, GIP, glucagon) — one of the most potent metabolic peptides in current research.
Tirzepatide
A dual GLP-1/GIP receptor agonist at the forefront of metabolic research.
For research use only. Not medical advice.